Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abcam plc stock logo
ABCZY
Abcam
$0.00
$11.26
$19.73
$3.98B1.294,712 shs5,400 shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$31.73
-2.5%
$36.80
$27.66
$121.06
$4.09B1.271.38 million shs5.77 million shs
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
$69.32
+11.2%
$66.96
$57.97
$141.74
$4.92B0.92924 shs249 shs
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abcam plc stock logo
ABCZY
Abcam
0.00%0.00%0.00%0.00%0.00%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-2.49%-13.23%-3.61%-59.66%-53.85%
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
+11.17%+9.30%+6.38%-29.62%-17.72%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abcam plc stock logo
ABCZY
Abcam
N/AN/AN/AN/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.287 of 5 stars
4.62.00.00.03.82.50.0
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abcam plc stock logo
ABCZY
Abcam
0.00
N/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10
Buy$136.50330.19% Upside
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
3.67
Strong BuyN/AN/A

Current Analyst Ratings Breakdown

Latest CU6, ZLDPF, PCVX, and ABCZY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
4/8/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
4/1/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$138.00 ➝ $100.00
4/1/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$157.00 ➝ $137.00
4/1/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$140.00 ➝ $90.00
3/31/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/12/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$160.00 ➝ $160.00
3/7/2025
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abcam plc stock logo
ABCZY
Abcam
$336.37M0.00N/AN/AN/ANaN
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$13.04 per shareN/A
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
$9.09M541.63N/AN/A$4.49 per share15.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abcam plc stock logo
ABCZY
Abcam
N/AN/A0.000.00N/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$402.27M-$3.99N/AN/AN/AN/A-23.53%-22.20%8/5/2025 (Estimated)
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
-$102.18M-$2.49N/AN/AN/A-1,725.03%-15.24%-13.77%N/A

Latest CU6, ZLDPF, PCVX, and ABCZY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.02-$1.04-$0.02-$1.04N/AN/A
5/8/2025Q1 2025
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
-$0.77-$0.67+$0.10-$0.67$248.61 million$1.14 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abcam plc stock logo
ABCZY
Abcam
$0.070.36%N/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abcam plc stock logo
ABCZY
Abcam
N/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
17.88
17.88
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
0.03
35.49
35.49

Institutional Ownership

CompanyInstitutional Ownership
Abcam plc stock logo
ABCZY
Abcam
N/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
N/A

Insider Ownership

CompanyInsider Ownership
Abcam plc stock logo
ABCZY
Abcam
N/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10%
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Abcam plc stock logo
ABCZY
Abcam
1,750205.08 millionN/ANot Optionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160129.00 million120.77 millionOptionable
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
34071.02 millionN/ANot Optionable

Recent News About These Companies

Zealand Pharma appoints Utpal Singh as CSO

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abcam stock logo

Abcam OTCMKTS:ABCZY

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Germany, the United Kingdom, and internationally. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. The company also offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc has partnership with Cancer Research UK for the development and commercialization of novel custom antibodies to support the acceleration of cancer research. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$31.73 -0.81 (-2.49%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$31.74 +0.01 (+0.03%)
As of 06:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Zealand Pharma A/S stock logo

Zealand Pharma A/S OTCMKTS:ZLDPF

$69.32 +6.96 (+11.17%)
As of 05/27/2025 03:26 PM Eastern

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.